// App-Quantinova.ai

TCT-657 : Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation Of Elixir DESyneTM Novolimus-Eluting Coronary Stent System With Durable Polymer To Endeavor Zotarolimus-Eluting Coronary Stent System: 3-Year Clinical and 9-Month Angiographic And IVUS Results: EXCELLA II Study

Researchers

Presenter

  • Stefan Verheye

Principal Investigators

  • Christophe Dubois

  • Karl-Eugen Hauptmann

  • John Ormiston

  • James Stewart

  • Joachim Schofer

  • Karl Stangl

  • Bernhard Witzenbichler

  • Marcus Wiemer

  • Emanuele Barbato

Medical Centers

  • Cardiovascular, Stanford, California

  • Herz-und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany

  • Krankenhaus der Barmherzigen Brueder, Trier, Trier, Germany

  • Medical Care Center Prof Mathey, Prof Schofer, Hamburg University Cardiovascular Center, Hamburg, Germany

  • Katholieke Universiteit Leuven, Leuven, Belgium

  • Charite Campus Benjamin Franklin, Berlin, Germany.

  • Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp, Belgium

  • Cardiovascular Center Aalst, Belgium, Aalst, Belgium

  • Professor, University of Auckland Medical School, Auckland, New Zealand

  • Auckland City Hospital, Auckland, New Zealand

  • Thoraxcenter, Erasmus Medical Center, Rotterdam, Rotterdam, Netherlands

Locations

  • Netherlands

  • Germany

  • United States

  • Belgium

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • ZoMaxx

  • Rapacan

  • Choline bitartrate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved